Merrimack Files S-1, But Life-Science IPO Market Far From Ironclad
This article was originally published in The Pink Sheet Daily
Executive Summary
The cancer drug maker aims to raise as much as $172.5 million and bring liquidity to investors who have poured in more than $250 million.